



# Financial Tear Sheet

## Corporate Profile

Blueprint Medicines is developing a new generation of highly selective and potent kinase medicines to improve the lives of patients with genomically defined diseases. The Company's approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. Blueprint Medicines is advancing three programs in clinical development for subsets of patients with gastrointestinal stromal tumors, hepatocellular carcinoma and systemic mastocytosis, as well as multiple programs in research and preclinical development. For more information, please visit [www.blueprintmedicines.com](http://www.blueprintmedicines.com).

## Primary IR Contact

Kristin Hodous

Blueprint Medicines

**Phone:** 617-714-6674

**E-mail:**

[khodous@blueprintmedicines.com](mailto:khodous@blueprintmedicines.com)

## Stock Information

### BPMC (Common Stock)

Exchange NASDAQ GS (US Dollar)

Price **\$66.90**

Change (%) ▼ **0.08 (0.12%)**

Volume 370,200

52 Week Low \$41.41

Market Cap \$2,936,224,832

Rolling EPS -4.34

PE Ratio 0

Shares Outstanding 43,837,337

Data as of July 16, 2018 4:00 p.m. ET



## Recent Press Releases & Upcoming Events

June 21, 2018

[Blueprint Medicines Initiates VOYAGER Phase 3 Clinical Trial of Avapritinib in Patients with Advanced Gastrointestinal Stromal Tumors](#)

June 15, 2018

[Blueprint Medicines Announces Updated Data from Ongoing Phase 1 EXPLORER Clinical Trial of Avapritinib in Patients with Advanced Systemic Mastocytosis Showing Profound and Durable Clinical Activity](#)

June 04, 2018

[Blueprint Medicines and CStone Pharmaceuticals Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Avapritinib, BLU-554 and BLU-667 in Greater China](#)

There are currently no events scheduled.

## SEC Filings

**Filing Date**

**Form**

## Corporate Governance

**Jeffrey Albers**

**Chief Executive**

June 25, 2018	4		Officer
June 25, 2018	4	Marion. Dorsch, Ph.D	Chief Scientific Officer
June 25, 2018	4		Officer
June 25, 2018	4	Anthony Boral, M.D-Ph.D.	Chief Medical Officer
		Kate Haviland	Chief Business Officer
		Christoph Lengauer, Ph.D.	Executive Vice President

Data provided by Nasdaq. Minimum 15 minutes delayed.